Komori
Pharma Foods International (2929) · InitiativeRaised

Growth Investment Through Construction of a New Pharmaceutical Plant

First written in FY2024. 3 of 5 entries say "Advanced", first in 2026-06-10. Latest entry: FY2026.

5entries
3years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024Advanced2026-06-10 – FY20262024: 120242025: 020252026: 42026
Same theme, other companies
Strengthening Pharmaceutical Production Sites and Meeting Quality StandardsA theme 7 companies write about · 0 as a headwind · 10 as a tailwind

0 other companies' latest entry also says "Raised".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026RaisedAnnual report

    「明治薬品㈱, Toyama Plant, new plant, 12,500, 3,657, internal funds and borrowings, July 2026, July 2028, production expansion」

    The new pharmaceutical plant project has a total cost of ¥12.5 billion, with ¥3.657 billion already paid, construction beginning in July 2026 and completion scheduled for July 2028. The investment increased from the previous plan of approximately ¥12 billion, and the project progressed to the construction stage.
  3. FY2024First statedAnnual report

    「To implement these initiatives, we will begin an ambitious investment program of approximately ¥30 billion over the next 5 years. Using this cash as a source of funds, in addition to growth investments such as the Eggshell Membrane Biomanufacturing Project, with a total investment of more than ¥5 billion, the construction of a new pharmaceutical plant at approximately ¥12 billion, and the development of GABA toward FDA GRAS certification in the United States, we will invest approximately ¥10 billion in M&A aimed at achieving discontinuous growth.」

    As part of the ¥30 billion-scale investment plan for the next 5 years, the company disclosed for the first time the construction of a new pharmaceutical plant costing approximately ¥12 billion.
Moved together

"Aggressive Business Investment to Achieve High Medium- to Long-Term Growth and Enhance Corporate Value" moved the same way as this thread, in the same document, in 4 of its 5 moves.

433333★123456
  1. ★This thread
  2. 1Aggressive Business Investment to Achieve High Medium- to Long-Term Growth and Enhance Corporate Value4×
  3. 2GABA Expansion in Japan and Overseas3×
  4. 3Development of antibody therapeutics using proprietary chicken antibody technology3×
  5. 4Raising Working Capital through Borrowings3×
  6. 5Development of Medicated Hair Growth Product Nyumo as a New Core Product3×
  7. 6SDG Initiatives Through the Upcycling of Underutilized Resources3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Pharma Foods International yet. It last moved in the General Meetings of Shareholders of 2026-10-02: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Growth Investment Through Construction of a New Pharmaceutical Plant | Pharma Foods International Co.,Ltd. (2929) | Komori